Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eli Lilly's donanemab shows promise in slowing Alzheimer's progression, offering significant market potential. Competitive landscape between Eli Lilly, Eisai, and Biogen could drive further innovation in Alzheimer's therapies.

Eli Lilly's Alzheimer's Breakthrough: A Game Changer For Investors And Patients

Eli Lilly's financial results were challenged by a recent decision from the FDA. The stock's dividend payout is modest but positioned to grow robustly.

Should Investors Buy This Hot Growth Stock?

The pharmaceutical giant's first-quarter results were hardly impressive. But the company's drug Mounjaro recently reported an important clinical win.

Here's the Best Reason to Buy Eli Lilly Stock Right Now

McKesson

Moderna

Demand for Moderna's COVID-19 vaccine will taper off this year, but investors remain bullish on its prospects. McKesson is a top distributor of pharmaceuticals and a key cog in the healthcare industry.

These Have Been 3 of the Best-Performing Healthcare Stocks Since 2020

Eli Lilly announced the successful results of a phase 3 trial with donanemab, an experimental treatment for Alzheimer's disease. Treatment with the Alzheimer's disease candidate appeared to reduce the rate of cognitive decline even better than another drug called Leqembi from Eisai and Biogen.

Should You Buy Eli Lilly Stock Now?

Donanemab slowed the decline in memory, in thinking and in the ability to conduct daily activities by 35%, according to Lilly's data.

FDA commissioner praises Eli Lilly Alzheimer's treatment results

Positive results from an Alzheimer's trial by Eli Lilly are seen as a very important step in the battle to fight the fatal disease, but questions remain about whether it will be covered by Medicare.

Eli Lilly's positive results from a Alzheimer's trial seen as ‘potentially very important'

Eli Lilly announced better-than-expected trial results for its early-stage Alzheimer's disease candidate, donanemab, today. The drug's latest results paint an encouraging picture for patients.

Why Eli Lilly Stock Is Bolting Higher Today

Sanofi

Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Sanofi (SNY) or Eli Lilly (LLY). But which of these two companies is the best option for those looking for undervalued stocks?

SNY or LLY: Which Is the Better Value Stock Right Now?

Biogen

The shares of Biogen Inc (NASDAQ:BIIB) are enjoying tailwinds from positive news surrounding sector peer Eli Lilly's (LLY) Alzheimer's drug  donanemab.

Biogen Stock Hits Fresh High on Eli Lilly Buzz

The company's Alzheimer's drug results might look better than Biogen's, but both makers will likely benefit.

Eli Lilly's Results Signal Arrival of Blockbuster New Drug Class

INDIANAPOLIS , May 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Securities 2023 Healthcare Conference, May 9-11, 2023. Patrik Jonsson, executive vice president, president of Lilly Immunology and Lilly USA, and chief customer officer, will participate in a fireside chat on Wednesday, May 10 at 1 p.m.

Lilly to Participate in Bank of America Securities 2023 Healthcare Conference

Eli Lilly (NYSE: LLY ) stock is getting a boost on Wednesday after the company announced results from an Alzheimer's clinical trial. The big news traders are celebrating is the effectiveness of donanemab as a treatment for Alzheimer's.

LLY Stock Alert: Eli Lilly Announces Positive Alzheimer's Drug Data

Eli Lilly stock popped Wednesday after the company said its experimental Alzheimer's treatment significantly slowed cognitive decline. The post Eli Lilly Surges After Alzheimer's Treatment Succeeds; Biogen Also Rises appeared first on Investor's Business Daily.

Eli Lilly Surges After Alzheimer's Treatment Succeeds; Biogen Also Rises

Eli Lilly and Co (NYSE:LLY) announced promising results for its experimental Alzheimer's drug, donanemab, in a closely watched late-stage trial. The drug met all goals of the trial and showed significant promise as an effective treatment for Alzheimer's disease.

Eli Lilly's experimental Alzheimer's drug slows cognitive decline, outperforming rivals in late-stage trial

After a large phase-three study demonstrated the success of its new drug for the treatment of Alzheimer's disease, the stock of pharmaceutical manufacturer and vendor Eli Lilly (NYSE: LLY) has increased by over 5% in premarket trading.

Eli Lilly (LLY) jumps 5% in premarket upon Alzheimer's drug study success

ImmunoGen

Markets were waiting to see what the Federal Reserve will do with interest rates later today. Eli Lilly announced favorable trial results for its Alzheimer's treatment.

Good News for Patients Is Lifting These 2 Biopharma Stocks

Advanced Micro Devices

Ford Motor Company

Starbucks

Livent Corp. shares LTHM jumped nearly 10% premarket Wednesday after the lithium miner posted first-quarter results that topped Wall Street views and raised guidance.

Eli Lilly jumps upon Alzheimer trial results, AMD, Starbucks and Ford drop after earnings, and other stocks on the move

The company says a Phase 3 study shows that donanemab 'significantly slowed cognitive and functional decline' in people with early symptomatic Alzheimer's disease.

Eli Lilly Stock Jumps on Positive Alzheimer's Drug Phase 3 Trial Data

Eli Lilly & Co.'s stock LLY jumped 4% premarket Wednesday, after the company announced positive data from a late-stage trial of its Alzheimer's disease treatment donanemab. The company said the Phase 3 trial showed that donanemab “significantly slowed cognitive and functional decline” in patients with early symptomatic Alzheimer's disease, and met its primary and all secondary endpoints.

Eli Lilly stock jumps 4% premarket on news of positive results in late-stage trial of Alzheimer's disease treatment

McDonald's

PepsiCo

It's been a tough 12 to 18 months for investors. The market roared higher into the end of 2021, stumbled big time in 2022, and had a strong start to 2023.

3 Stocks Quietly Hitting All-Time Highs (and Can Continue Higher)

Donanemab, a monthly antibody infusion made by pharmaceutical company Eli Lilly, also significantly reduced brain plaque associated with Alzheimer's disease.

Eli Lilly Alzheimer's treatment donanemab slowed disease progression in clinical trial

Nearly half (47%) of the participants on donanemab (compared to 29% on placebo) had no clinical progression at 1 year (defined as no decline in CDR-SB) Phase 3 trial met primary endpoint and all secondary endpoints measuring cognitive and functional decline Donanemab treatment slowed clinical decline by 35% compared to placebo, and resulted in 40% less decline on the ability to perform activities of daily living Over half of all participants completed their course of treatment by 12 months  INDIANAPOLIS , May 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today positive results of the TRAILBLAZER-ALZ 2 Phase 3 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease. Donanemab met the primary endpoint of change from baseline until 18 months on the integrated Alzheimer's Disease Rating Scale (iADRS).

Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease

INDIANAPOLIS , May 2, 2023 /PRNewswire/ -- To remove barriers and create more equitable, affordable post-high school education opportunities for Indiana's growing immigrant population, Eli Lilly and Company (NYSE: LLY) today announced grants totaling $500,000 to four local nonprofits that offer education assistance to Deferred Action for Childhood Arrivals (DACA) recipients, also known as Dreamers. Currently, Indiana is one of only two states that does not offer DACA eligible students living in Indiana in-state tuition to its state-run colleges and universities.

Lilly Provides $500,000 in Grants to Support Equitable Access to Education for Dreamers in Indiana

Eli Lilly is facing stiff but short-term headwinds to its earnings. Its dividend isn't in any danger, and it'll likely continue to rise -- and quickly.

News for Eli Lilly Stock (LLY)